Value Adjusted for Debt and Cash: Neumora Corp (NMRA)

Brandmark of neumoratx.com (NMRA)

Neumora Therapeutics (NMRA) is facing a liquidity shortage and a gradual depletion of funds due to massive R&D expenditures. External risks are linked to logistical disruptions in raw material supplies and complexities regarding international patenting. The Enterprise Value price action is currently at 5.42. The business relies on data analysis to develop innovative drugs for severe psychiatric pathologies, strengthening its status as a scientific leader.

NMRA Neumora Corp: Total Company Value in the range 11/23/2025 - 10/31/2026

Neumora Therapeutics - analytical breakdowns and key metrics (NMRA)

- current quotes and average value forecast:
Stock Quotes Neumora|NMRA - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Neumora Therapeutics|NMRA - Enterprise Value
- book capitalization information:
Book Value per Share Neumora Therapeutics|NMRA - Company Book Value|Capitalization to Book Value Ratio neumoratx.com|NMRA - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital Neumora Therapeutics|NMRA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital neumoratx.com|NMRA - Company Debts|Debt to Net Assets Ratio Neumora Therapeutics|NMRA - Company Long-Term Debt|Short-Term Debt Neumora Therapeutics|Immediate Liquidity Ratio neumoratx.com
- business earnings and investment ratios data:
NMRA - Net Profit
Analysis of all company metrics:Neumora
Manufactured product of Neumora Therapeutics

To protect capital from volatility, it is crucial for investors to distinguish between market value and the actual buyout price of a business, which consists of market capitalization and net debt. Analyzing the evolution of business value reveals that the R&D-stage risks for Neumora Therapeutics (NMRA) are already priced in, and the upcoming Phase 2 results for its antidepressant make this metric a key indicator of the company's fair valuation ahead of potential growth.

Competitors of Neumora Therapeutics (NMRA)

BIIB - Real Price to Acquire Entire Company|NBIX - Total Company Value|Value Adjusted for Debt and Cash RGC (Regencell Corp)|AXSM: Enterprise Value|acadia-pharm.com (ACAD) - Enterprise Value|Total Company Value Xenon|Business Value VKTX (Viking Therapeutics Inc)|Enterprise Value SUPN|CPRX - Total Enterprise Value|Denali Therapeutics - Real Price to Acquire Entire Company|Enterprise Value harmonybiosciences.com HRMY|BHVN - Total Company Value|Value Adjusted for Debt and Cash AMLX (Amylyx Pharmaceuticals Inc)|Trevi Pharma (TRVI) - Total Company Value|Total Enterprise Value Praxis Corp (PRAX)|Total Company Value Anavex Life Sciences|Business Value CBLL (ceribell.com)|Enterprise Value PRTA|ALEC - Total Enterprise Value|Annexon Inc. - Real Price to Acquire Entire Company|Enterprise Value Omeros Corp OMER|NGNE - Total Company Value|acimmune.com (ACIU) - Real Price to Acquire Entire Company|Voyager Therapeutics, Inc. (VYGR) - Total Company Value|Total Enterprise Value Scilex Holding (SCLX)|Total Company Value Tevogen Bio Holdings, Inc.|ACOG: Value Adjusted for Debt and Cash|Enterprise Value CGTX|Enterprise Value inhibikase.com (IKT)|Cassava Sciences - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash ASRT|COYA: Real Price to Acquire Entire Company|Vistagen Therapeutics - Aggregate Business Value|OVID: Enterprise Value|acumenpharm.com - Value Adjusted for Debt and Cash|CRVO (CervoMed) - Enterprise Value|Total Enterprise Value Alterity Therapeutics Ltd ATHE|Total Company Value Clene Inc. (CLNN)|PEPG (pepgen.com) - Value Adjusted for Debt and Cash|Enterprise Value JUNS (Jupiter Neurosciences)|Enterprise Value relmada.com RLMD|ANVS - Total Company Value|Full Business Value GRCE|AIFF: Enterprise Value|Total Enterprise Value Klotho Neurosciences (KLTO)|Real Price to Acquire Entire Company NRSN|Enterprise Value revivapharma.com|Real Price to Acquire Entire Company MTVA (MetaVia Inc)|Aggregate Business Value NRXS|Enterprise Value HSDT (Helius Medical Technologies)|Company Buyout Price Passage Bio Inc. (PASG)|Neuphoria - Enterprise Value|minervaneurosciences.com (NERV) - Real Price to Acquire Entire Company|Athira Pharma (ATHA) - Total Company Value|ADXN - Company Buyout Price|Total Company Value Alzamend Neuro Inc.|Business Value CYCN (Cyclerion)|Total Company Value Protagenic Therapeutics (PTIX)|Real Price to Acquire Entire Company pasitheaclinics.com KTTA|Total Company Value Cortigent CRGT|Value Adjusted for Debt and Cash ATXI|Brainstorm Cell Therapeutics, Inc. - Enterprise Value|CARA - Enterprise Value|Chromocell Therapeutics (CHRO) - Total Company Value|Business Value ELYM|ITCI (Intra-Cellular Therapies Inc.) - Enterprise Value|Total Enterprise Value Longboard Pharmaceuticals Inc LBPH|Real Price to Acquire Entire Company MRNS (Marinus)|Enterprise Value NKGen Biotech Corp (NKGN)|Total Company Value NeuroBo Pharmaceuticals NRBO|Value Adjusted for Debt and Cash SAGE|SNPX - Total Company Value|Total Enterprise Value Trevena Inc.|vigilneuro.com (VIGL) - Total Company Value|Business Value WENA|CERE (Cerevel Therapeutics) - Enterprise Value